AptarGroup（ATR）株式概要
AptarGroup, Inc.は、医薬品、フレグランス、フェイシャルスキンケア、カラー化粧品、パーソナルケア、ホームケア、食品・飲料市場向けに、ドラッグデリバリー、消費者製品ディスペンシング、活性物質科学ソリューションとサービスを設計・製造している。 詳細
ATR Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AptarGroup, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$125.53 |
| 52週高値 | US$164.28 |
| 52週安値 | US$103.23 |
| ベータ | 0.38 |
| 1ヶ月の変化 | 6.63% |
| 3ヶ月変化 | -4.18% |
| 1年変化 | -20.33% |
| 3年間の変化 | 5.26% |
| 5年間の変化 | -8.46% |
| IPOからの変化 | 2,474.97% |
最新ニュース
Seeking Alpha • Jun 29
AptarGroup Has Fallen Enough (Rating Upgrade)
Summary AptarGroup is upgraded from 'sell' to 'hold' as valuation improves after a significant share price decline. ATR's Q1 revenue rose 10.8% to $982.9M, but most growth was driven by FX and acquisitions, not organic expansion. Cash flows and EBITDA improved despite margin compression and net profit declines, particularly due to Beauty segment strength. ATR trades at a premium to peers, justified by its niche positioning, but not enough for a 'buy' rating. Read the full article on Seeking Alpha分析記事 • Jun 18
AptarGroup (ATR) Stock Could Be 25.5% Undervalued on Its Drug Delivery Growth Narrative
Why AptarGroup Stock Is Back On Investor Radars AptarGroup (ATR) has drawn interest after recent share price moves, with the stock gaining about 6% over the past month while still showing a decline over the past year. For investors tracking AptarGroup as a packaging and drug delivery supplier, those mixed return figures may prompt a closer look at how its current valuation lines up with recent business performance and market expectations. See our latest analysis for AptarGroup. With the share...
ナラティブの更新 • Jun 17
ATR: Healthcare Packaging And Refillable Beauty Will Drive Future Upside Potential
The analyst price target for AptarGroup has been adjusted slightly to $211.14 from $211.25. Analysts cite updated assumptions for revenue growth, profit margins and the future P/E multiple as the main drivers of the change.Recent updates
Seeking Alpha • Jun 29
AptarGroup Has Fallen Enough (Rating Upgrade)
Summary AptarGroup is upgraded from 'sell' to 'hold' as valuation improves after a significant share price decline. ATR's Q1 revenue rose 10.8% to $982.9M, but most growth was driven by FX and acquisitions, not organic expansion. Cash flows and EBITDA improved despite margin compression and net profit declines, particularly due to Beauty segment strength. ATR trades at a premium to peers, justified by its niche positioning, but not enough for a 'buy' rating. Read the full article on Seeking Alpha分析記事 • Jun 18
AptarGroup (ATR) Stock Could Be 25.5% Undervalued on Its Drug Delivery Growth Narrative
Why AptarGroup Stock Is Back On Investor Radars AptarGroup (ATR) has drawn interest after recent share price moves, with the stock gaining about 6% over the past month while still showing a decline over the past year. For investors tracking AptarGroup as a packaging and drug delivery supplier, those mixed return figures may prompt a closer look at how its current valuation lines up with recent business performance and market expectations. See our latest analysis for AptarGroup. With the share...ナラティブの更新 • Jun 17
ATR: Healthcare Packaging And Refillable Beauty Will Drive Future Upside Potential
The analyst price target for AptarGroup has been adjusted slightly to $211.14 from $211.25. Analysts cite updated assumptions for revenue growth, profit margins and the future P/E multiple as the main drivers of the change.ナラティブの更新 • Jun 03
ATR: Healthcare Packaging And Refillable Beauty Will Support Future Upside Potential
Analysts have nudged their price target for AptarGroup higher by refining assumptions on revenue growth to 6.11%, profit margin to 9.78%, and a future P/E of 33.28x. This lifts their valuation outlook without changing the underlying fair value estimate of $211.25 per share.ナラティブの更新 • May 12
ATR: Refillable Beauty And Nasal Drug Delivery Will Support Upside Potential
AptarGroup's updated analyst price target has edged down by about $1.54 to reflect slightly higher discount rate assumptions, along with modest adjustments to projected revenue growth, profit margins, and future P/E expectations, according to analysts. What's in the News AptarGroup and Clarins rolled out a custom reloadable airless packaging solution for Clarins Total Eye Lift Eye Cream, using Aptar Beauty’s patented Gaïa technology to support lower material usage while maintaining formula protection and a premium look.分析記事 • May 03
Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...
ナラティブの更新 • Apr 28
ATR: Nasal Therapies And Share Buybacks Will Support Future Upside
Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.ナラティブの更新 • Apr 14
ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside
Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).ナラティブの更新 • Mar 30
ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside
Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.ナラティブの更新 • Mar 16
ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio
Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.ナラティブの更新 • Mar 02
ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential
Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.
ナラティブの更新 • Feb 16
ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns
Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.ナラティブの更新 • Feb 02
ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook
AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).ナラティブの更新 • Jan 19
ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns
Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).ナラティブの更新 • Jan 05
ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns
Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.分析記事 • Jan 02
We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...ナラティブの更新 • Dec 15
ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential
Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.ナラティブの更新 • Nov 30
ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside
Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).ナラティブの更新 • Nov 16
ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside
Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).ナラティブの更新 • Nov 01
ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions
Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.分析記事 • Oct 18
AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48
The board of AptarGroup, Inc. ( NYSE:ATR ) has announced that it will be increasing its dividend by 6.7% on the 13th of...ナラティブの更新 • Sep 05
Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare
The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.分析記事 • Aug 28
AptarGroup, Inc.'s (NYSE:ATR) Business Is Trailing The Market But Its Shares Aren't
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...分析記事 • Jul 15
AptarGroup's (NYSE:ATR) Dividend Will Be $0.45
AptarGroup, Inc. ( NYSE:ATR ) will pay a dividend of $0.45 on the 14th of August. The dividend yield is 1.1% based on...Seeking Alpha • Dec 02
AptarGroup Has Gotten Too Expensive
Summary AptarGroup specializes in niche packaging solutions for pharmaceuticals, beauty, food, and personal care, with impressive growth and a strong market presence. Despite recent stock performance, I find AptarGroup shares expensive, leading me to downgrade from 'hold' to a 'soft sell' rating. The company's financials show revenue and profitability growth, but valuation metrics indicate shares are overvalued compared to peers. AptarGroup's robust balance sheet and share buyback program are positives, but high trading multiples warrant a more cautious investment stance. Read the full article on Seeking Alpha株主還元
| ATR | US Packaging | US 市場 | |
|---|---|---|---|
| 7D | -0.4% | -2.4% | 0.1% |
| 1Y | -20.3% | -8.2% | 20.3% |
業界別リターン: ATR過去 1 年間で-8.2 % の収益を上げたUS Packaging業界を下回りました。
リターン対市場: ATRは、過去 1 年間で20.3 % のリターンを上げたUS市場を下回りました。
価格変動
| ATR volatility | |
|---|---|
| ATR Average Weekly Movement | 3.4% |
| Packaging Industry Average Movement | 6.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: ATR 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: ATRの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1992 | 14,000 | Stephan Tanda | www.aptar.com |
AptarGroup, Inc.は、医薬品、フレグランス、フェイシャルスキンケア、カラーコスメティクス、パーソナルケア、ホームケア、食品・飲料市場向けに、ドラッグデリバリー、消費者製品ディスペンシング、アクティブマテリアルサイエンスのソリューションとサービスを設計・製造している。同社は3つのセグメントで事業を展開している：ファーマ、ビューティー、クロージャー。非加圧容器からスプレー、液体、ローションを吐出するディスペンシングポンプ、医薬品やフレグランス用途のファインミストポンプ、粘性製剤用のローションポンプ、さらにキャップを外さずに製品を供給できるディスペンシングソリューションやノン・ディスペンシングソリューションなどのクロージャーを提供し、様々な消費者エンドマーケットで使用されている。また、医薬品、パーソナルケア、家庭用アプリケーション向けに、加圧容器や連続噴霧・定量投与バルブに使用されるエアゾールバルブ、エラストマー一次包装部品、アクティブマテリアルサイエンスソリューション、デジタルヘルスソリューションも提供している。同社は主にアジア、欧州、中南米、北米で製品とサービスを販売している。AptarGroup, Inc.は1992年に設立され、イリノイ州クリスタルレイクに本社を置いている。
AptarGroup, Inc. 基礎のまとめ
| ATR 基礎統計学 | |
|---|---|
| 時価総額 | US$8.01b |
| 収益（TTM） | US$386.67m |
| 売上高(TTM) | US$3.87b |
20.7x
PER（株価収益率2.1x
P/SレシオATR は割高か？
公正価値と評価分析を参照収益と収入
| ATR 損益計算書（TTM） | |
|---|---|
| 収益 | US$3.87b |
| 売上原価 | US$2.45b |
| 売上総利益 | US$1.42b |
| その他の費用 | US$1.03b |
| 収益 | US$386.67m |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 30, 2026
| 一株当たり利益（EPS） | 6.06 |
| グロス・マージン | 36.67% |
| 純利益率 | 9.98% |
| 有利子負債／自己資本比率 | 51.2% |
ATR の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
1.5%
現在の配当利回り31%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/13 04:26 |
| 終値 | 2026/07/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
AptarGroup, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Ghansham Panjabi | Baird |
| Mark Wilde | BMO Capital Markets Equity Research |
| George Staphos | BofA Global Research |